Abstract
The study was performed on 48 subjects divided into four groups: control (1), hypercholesterolemia (2), hypertriglyceridemia (3) and mixed hyperlipidemia (4), The concentration and pharmacokinetic parameters for total phenytoin were determined after a single oral dose of 300 mg. Hypercholesterolemia (HCh) and mixed hyperlipidemia (MHL) significantly influenced the pharmacokinetics of total phenytoin, while hypertriglyceridemia (HTG) was without effect. The mean serum concentration of phenytoin was significantly higher in the HCh and MHL groups as compared with the control from 12 to 72 h. A significant increase in AUC, and tmax was observed in the HCh group. No significant changes were found in the HTG group. In the MHL group, AUC increased and ct/F/bw decreased. It was shown that hypercholesterolemia and mixed hyperlipidemia change the pharmacokinetics of phenytoin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
